WilmerHale Advises TRIANA Biomedicines on $120M Series B Financing

WilmerHale Advises TRIANA Biomedicines on $120M Series B Financing

Client News

Related Solutions

Helping clients launch their businesses and transform their innovative ideas into successful companies.
Comprehensive counseling for healthcare providers, insurers and the companies that supply them with products and services.
Advising life sciences innovators, investors and industry leaders on complex transactions, legal issues and business challenges.

WilmerHale advised TRIANA Biomedicines, Inc. (TRIANA), a leading biopharmaceutical company focused on advancing a target-first and proximity-first molecular glue discovery platform to address difficult to drug disease targets, in the successful closing of its oversubscribed $120 million Series B financing round. The proceeds from the financing will support development of Triana’s lead product candidate TRI-611, an anaplastic lymphoma kinase–positive (ALK) targeted molecular glue degrader, to clinical proof of concept in ALK+ non-small cell lung cancer (NSCLC), selection of a second product candidate, and the advancement of TRIANA’s product pipeline beyond TRI-611. 

The WilmerHale team advising TRIANA was led by Stuart Falber and included Hilary Baker Jennings, Helen Park and Eugena Liu.

Notice

We appreciate your interest in WilmerHale. While we are pleased to have you contact us, please keep in mind that merely contacting WilmerHale does not create an attorney-client relationship. Such a relationship will not arise until the Firm agrees in writing to represent you in connection with a particular matter. Importantly, unless and until this has occurred, you should not provide us with any confidential information, and we have no duty to keep confidential any information that we may receive from you. Thank you for your understanding.

I Accept Cancel